Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexaria Bioscience (LEXX) Total Liabilities (2016 - 2026)

Lexaria Bioscience's Total Liabilities history spans 12 years, with the latest figure at $276997.0 for Q1 2026.

  • Quarterly results put Total Liabilities at $276997.0 for Q1 2026, down 85.55% from a year ago — trailing twelve months through Feb 2026 was $276997.0 (down 85.55% YoY), and the annual figure for FY2025 was $1.6 million, up 30.08%.
  • Total Liabilities for Q1 2026 was $276997.0 at Lexaria Bioscience, down from $1.5 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $1.9 million in Q1 2025 to a low of $194623.0 in Q1 2022.
  • The 5-year median for Total Liabilities is $281520.0 (2022), against an average of $702041.9.
  • The sharpest move saw Total Liabilities surged 838.67% in 2025, then tumbled 85.55% in 2026.
  • Year by year, Total Liabilities stood at $281520.0 in 2022, then fell by 9.76% to $254040.0 in 2023, then skyrocketed by 57.34% to $399718.0 in 2024, then soared by 282.11% to $1.5 million in 2025, then crashed by 81.86% to $276997.0 in 2026.
  • According to Business Quant data, Total Liabilities over the past three periods came in at $276997.0, $1.5 million, and $1.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.